With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

Submitted by admin on October 2, 2023 - 6:36pm

Source:

Fierce Pharma

News Tags:

Novo Nordisk

Rivfloza

FDA

primary hyperoxaluria type 1

RNAi

Alnylam

Headline:

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

snippet:

Novo Nordisk has spent the last few years grappling with the demands stemming from the launch of its popular obesity therapy Wegovy. Now, with a new FDA approval, the drugmaker is making a splash in a much rarer disease.

Search form

You are here

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam

With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam